Prospective multicenter randomised comparison of standalone Hydrus vs two iStents for reduction of IOP in open-angle glaucoma: the Compare study

Session Details

Session Title: Moderated Poster Session: New and Interesting

Venue: Poster Village: Pod 1

First Author: : A.Fea ITALY

Co Author(s): :                           

Abstract Details

Purpose:

To compare differences in medication required to maintain intraocular pressure (IOP) in open angle glaucoma (OAG) for two microinvasive glaucoma surgery (MIGS) devices

Setting:

The study recruited volunteers from 12 clinical practices located in 9 countries in Europe, South America, Asia, and the Middle East with open angle glaucoma. Local ethics committee approval was obtained at all sites and informed consent was obtained prior to study participation

Methods:

This was a prospective, multicenter randomized clinical trial. 152 eyes on ≥2 hypotensive medications and washed out diurnal IOP between 23-39 mm Hg were randomized 1:1 on the day of surgery to either single Hydrus Microstent (Ivantis, Irvine, CA) or two GTS100 iStent Trabecular Micro-Bypass Stents (Glaukos, San Clemente, CA) . There was no concomitant cataract surgery. Follow up was conducted at 1, 3, 6, and 12 months postoperative

Results:

Hydrus Microstent (HMS) and 2 iStent (2IS) groups were matched for age, ethnicity, lens status, visual acuity and glaucoma severity (Humphrey SITA 24-2 visual field). At 12 months, the proportion of patients with 1 or more glaucoma medications reduced and a 20% or more reduction in IOP was 82.2% and 61.3% for HMS and 2IS, respectively (difference = 20.9%, p=0.0061). The mean change in medications at 12 months was -1.6±1.2 in the HMS group vs. -1.0±1.2 for the 2IS group (p<0.001 vs. baseline, difference in change = -0.6 medications, p = 0.004).

Conclusions:

Both Schlemm's canal based MIGS devices reduced medication count at 12 months compared to preoperative. The medication reduction in the HMS group was significantly greater than in the 2IS group, as was response to treatment based defined as reduction of 1 medication and 20% reduction in IOP.

Financial Disclosure:

None